Last updated 41 days ago

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

1405 patients around the world
Available in Peru
Merck Sharp & Dohme Colombia S.A.S.
2Research sites
1405Patients around the world
This study is for people with
Bladder Cancer
Non-muscle-invasive bladder cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Clínica Oncosalud
Recruiting
Jirón García Naranjo 840, La Victoria 13
Hospital Militar Central
Recruiting
Pje. Quiñones 195, Lima 15076
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy